The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.

Xiaolong Tang(Shenzhen University Health Science Center), Yong Liang, Jingjing Dai(Nanjing Medical University), Chao Zhang(Sun Yat-sen University), Jia Wei(Anhui University of Science and Technology), Ke Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Qingguo Li(Xuzhou Medical College), Wei Hou(Guangxi Medical University), Yubao Xue(Xuzhou Medical College), Donghui Zheng(Nanjing Tech University), Yongqiang Zhu(Anhui University of Science and Technology), Wenxuan Ni(Anhui University of Science and Technology), Xiaojun Feng(Wuxi People's Hospital)
PubMed
January 1, 2015
Cited by 22

Related Papers

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
|Proceedings of the National Academy of Sciences|2017|899
Smartphone-based platforms implementing microfluidic detection with image-based artificial intelligence
|Nature Communications|2023|248
Chemically Edited Exosomes with Dual Ligand Purified by Microfluidic Device for Active Targeted Drug Delivery to Tumor Cells
|ACS Applied Materials & Interfaces|2017|218
Designer Exosomes for Active Targeted Chemo‐Photothermal Synergistic Tumor Therapy
|Advanced Functional Materials|2018|188
The use of RGD-engineered exosomes for enhanced targeting ability and synergistic therapy toward angiogenesis
|Nanoscale|2017|164